JPWO2022040545A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022040545A5
JPWO2022040545A5 JP2023512139A JP2023512139A JPWO2022040545A5 JP WO2022040545 A5 JPWO2022040545 A5 JP WO2022040545A5 JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023512139 A JP2023512139 A JP 2023512139A JP WO2022040545 A5 JPWO2022040545 A5 JP WO2022040545A5
Authority
JP
Japan
Prior art keywords
disorder
disorders
compound
compound according
status epilepticus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539125A5 (https=
JP2023539125A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046935 external-priority patent/WO2022040545A1/en
Publication of JP2023539125A publication Critical patent/JP2023539125A/ja
Publication of JPWO2022040545A5 publication Critical patent/JPWO2022040545A5/ja
Publication of JP2023539125A5 publication Critical patent/JP2023539125A5/ja
Pending legal-status Critical Current

Links

JP2023512139A 2020-08-20 2021-08-20 有機化合物 Pending JP2023539125A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068222P 2020-08-20 2020-08-20
US63/068,222 2020-08-20
PCT/US2021/046935 WO2022040545A1 (en) 2020-08-20 2021-08-20 Organic compounds

Publications (3)

Publication Number Publication Date
JP2023539125A JP2023539125A (ja) 2023-09-13
JPWO2022040545A5 true JPWO2022040545A5 (https=) 2024-08-28
JP2023539125A5 JP2023539125A5 (https=) 2024-08-28

Family

ID=80350596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512139A Pending JP2023539125A (ja) 2020-08-20 2021-08-20 有機化合物

Country Status (4)

Country Link
US (1) US20230416300A1 (https=)
EP (1) EP4200312A4 (https=)
JP (1) JP2023539125A (https=)
WO (1) WO2022040545A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
CN116606341A (zh) * 2022-07-28 2023-08-18 上海醇健实业发展有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物
EP4650359A1 (en) * 2022-07-28 2025-11-19 Hunan Kyf Pharmaceutical. Co., Ltd. Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof
WO2024059608A1 (en) * 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024230797A1 (zh) * 2023-05-11 2024-11-14 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
KR100338287B1 (ko) * 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
US10577390B2 (en) * 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3229350B1 (en) * 2016-04-08 2021-06-23 Black & Decker Inc. Brushless motor for a power tool
EP3720867A1 (en) * 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
EP3728284B1 (en) * 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
AU2019406803B2 (en) * 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid

Similar Documents

Publication Publication Date Title
CN100455560C (zh) 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途
JP2021519267A5 (https=)
JP2017531020A5 (https=)
JP2018505898A5 (https=)
US5552418A (en) Trisubstituted Naphthylalkylamides
JP2009531277A5 (https=)
CA2636324A1 (en) Cycloalkylamines as monoamine reuptake inhibitors
JP2009527462A5 (https=)
IL262177A (en) Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders
RU2017130909A (ru) Композиции интенсивного проникновения и их применение
JPWO2022040545A5 (https=)
AU2011324414B2 (en) Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
EP4426686A1 (en) N,n-dimethylamphetamine analogs for treating brain disorders
CA2870240A1 (en) Analgesic
WO1999066920A1 (en) The use of valproic acid analog for the treatment and prevention of migraine and affective illness
JPWO2020131918A5 (https=)
CN113717133B (zh) 3-酰胺基-n-芳基苯甲酰胺类化合物及应用
RU2021119458A (ru) Органические соединения
JPWO2021142477A5 (https=)
HUE024560T2 (hu) Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére
AP410A (en) Diamines in the treatment of arrhythmia.
RU2125045C1 (ru) 2,6-диметиланилиды n-циклопропилпиперидин-2-карбоновых кислот и фармацевтически приемлемые соли с кислотами и способ их получения
CN113425720A (zh) 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途
RU2025117909A (ru) Соединение ингибитора пиридазина nlrp3, фармацевтическая композиция, способ его получения и его применение
JPH05503510A (ja) 光学的に純粋な（ｓ）―アテノロールを含む組成物と方法